Daniel Brungs

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Danny Rischin, Sandro Porceddu, Fiona Day et al. · New England Journal of Medicine · 2025 · 60 citations

Medicine, Oncology, Pharmacotherapy +17

Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer

Daniel Brungs, Elahe Minaei, Ann‐Katrin Piper et al. · Scientific Reports · 2020 · 48 citations · Full text

Medicine, Cell Biology, Pathobiology +17

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13

Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer

Daniel Brungs, Morteza Aghmesheh, Paul de Souza et al. · Clinical Colorectal Cancer · 2018 · 46 citations

Medicine, Geriatric Medicine, Oncology +15